Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06081517 · ClinicalTrials.gov registry record
Evaluating Disparities in Precision Oncology
A clinical trial of Advanced Cancer and Metastatic Cancer, sponsored by Indiana University.
- Recruiting
- Registry status
- 10,600
- Enrollment target
- 1
- Study location
NCT06081517: Recruiting study of Advanced Cancer and Metastatic Cancer, sponsored by Indiana University.
NCT06081517 is a study of Advanced Cancer and Metastatic Cancer that is actively recruiting participants, run by Indiana University. The registered enrollment target is 10,600 participants, above the 159-participant average among 122 other Advanced Cancer trials with a reported enrollment target (6567% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06081517, a study of Advanced Cancer and Metastatic Cancer, is actively recruiting participants, sponsored by Indiana University.
- RECRUITING
- Registry status
- 10,600 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a non-randomized observational trial designed to collect detailed clinical, social determinant, and genomic data from patients enrolled in molecular oncology tumor boards across four comprehensive cancer centers.
Conditions Studied
Interventions
- BEHAVIORAL Social Determinants of Health and toxicity questionnaires
Study Locations (1)
Indiana
- Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,600 participants |
| Start Date | 2024-01-26 |
| Est. Completion | 2028-12 |
What NCT06081517 shows while recruiting
NCT06081517 is an observational study that tracks outcomes without assigning an intervention. Its 10,600 participants enrollment target places it among the larger protocols in the corpus, above the 159-participant average among 122 other Advanced Cancer trials with a reported enrollment target (6567% higher).
The record links to 2 conditions, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which Social Determinants of Health and toxicity questionnaires is the first listed.
NCT06081517 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT06081517 about?
NCT06081517 is a clinical study titled "Evaluating Disparities in Precision Oncology". This is a non-randomized observational trial designed to collect detailed clinical, social determinant, and genomic data from patients enrolled in molecular oncology tumor boards across four comprehensive cancer centers.
What is the current status of trial NCT06081517?
This trial is currently recruiting. The enrollment target is 10,600 participants. The study started on 2024-01-26. Estimated completion is 2028-12.
What conditions does trial NCT06081517 study?
This clinical trial studies the following conditions: Advanced Cancer, Metastatic Cancer.
What interventions are being tested in trial NCT06081517?
The interventions under investigation include: Social Determinants of Health and toxicity questionnaires (BEHAVIORAL).
Who is sponsoring clinical trial NCT06081517?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06081517 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06081517's enrollment target sits among peer trials
10,600 1st of 122 higher than 122 of 122 other Advanced Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BOLSTER: Learning New Skills to Thrive
RECRUITING · NA
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer
RECRUITING · NA
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Pilot Trial of Spiritual Care Interventions for Patients With Cancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05759299 · 10,500 participants
International obServational sTudy on AiRway manaGement in operAting Room and Non-operaTing Room anaEsthesia
- NCT06891222 · 10,500 participants
A Study of Electrocardiogram and Focused Cardiac Ultrasound for Enhanced Cardiac Disease Screening
- NCT06468202 · 10,742 participants · Phase 4
Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL
- NCT07157774 · 10,450 participants · Phase 3
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI